Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study from Athens, Greece, there was no evidence linking prostate cancer with vertex baldness, smoking, coffee, or alcohol, but urban living and early adulthood sexual activity may influence risk.

This article outlines the synthesis of spiro[cyclohexane‐1,2′‐[2 H ]indene] derivatives similar to known steroid 5α‐reductase inhibitors, but it does not report experimental findings.

This study from Athens, Greece observed that urban living may increase prostate cancer risk, while early adulthood sexual activity might inversely relate to this risk.

This study provides evidence supporting the feasibility of presurgical, window-of-opportunity models to evaluate the preventive potential of candidate agents in cancer, using cases from breast, prostate, and colorectal settings.

This study indicates that the normal human prostate is not a major contributor to circulating blood DHT concentrations in androgen-deficient patients receiving testosterone replacement therapy.

This study explores the clinical significance of the intravesical prostatic protrusion/prostate volume ratio in diagnosing bladder outlet obstruction but reports no new results.

This study found that women with polycystic ovary syndrome had significantly higher levels of prostate-specific antigen, which positively correlated with testosterone levels, the LH/FSH ratio, and hirsutism severity.

In this case study, a 3-year-old German Shepherd treated for an enlarged prostate with medication and surgery showed a significant prostate size reduction by 93.9% over 138 days, ruling out neoplastic processes.

In this study, men with early-onset androgenetic alopecia were found to have a higher risk of prostate cancer, suggesting early screening could be beneficial for these individuals.

In this study, researchers found that shorter CA repeats in the ERbeta gene are correlated with PSA expression, and PSA immunoexpression is associated with increased disease-free survival in breast cancer.

This study suggests that male pattern baldness—especially moderate to severe—is an independent risk factor for prostate cancer and high-grade disease in men undergoing prostate biopsy.

This study examined the most common chemotherapy side effects among patients with prostate, bladder, and testicular cancer, noting hair loss, fatigue, and decreased appetite as frequent symptoms.

This study found that PSA concentrations in peripheral blood are related to androgen levels, suggesting that PSA is a valuable marker for diagnosing hyperandrogenism in women.

This study found that men with early-onset androgenetic alopecia before age 31 have a significantly increased risk of developing prostate cancer.

This review found that finasteride monotherapy for managing LUTS/BPH significantly reduced prostate volume and improved symptoms, with sexual dysfunctions reported as notable side effects compared to placebo, but emphasizes the need for more comprehensive studies.

This study found that high-dose pterostilbene potentially reduced prostate hyperplasia and had strong antioxidant effects in male rats with benign prostatic hyperplasia, suggesting it might be more effective than vitamin C and resveratrol in similar contexts.

This study found a positive association between erectile dysfunction and the functionality of the marital subsystem in patients with benign prostatic hyperplasia treated with tamsulosin and finasteride.

In this retrospective cohort study, researchers found no significant difference between finasteride and dutasteride in terms of reducing prostate volume or adverse effects among patients with benign prostatic hyperplasia, although both drugs improved lower urinary tract symptoms over one year by reducing prostate volume.

This study found no significant association between male pattern baldness and benign prostatic hyperplasia.

This study found that the combination of finasteride and doxazosina was more effective in reducing the long-term progression of benign prostatic hyperplasia compared to monotherapy.

This study observed no association between androgenetic alopecia and benign prostatic hyperplasia in men aged 20 and older, although a positive family history was linked to early onset of hair loss.

This study found that five years after prostatic surgery for male lower urinary tract symptoms associated with benign prostatic obstruction, 12% of patients required a second surgery, with prior prostatitis identified as a significant risk factor for reintervention.

This study found that among men with Benign Prostatic Hyperplasia, treatment with the 5α-reductase inhibitor finasteride for three months significantly reduced levels of dihydrotestosterone and estradiol, hormones involved in prostate enlargement, without altering follicle-stimulating hormone or luteinizing hormone levels.

The literature review concluded that while 5α-reductase inhibitors hold promise for managing prostate cancer, they raise significant safety concerns regarding their association with high-grade tumors and mortality, highlighting the need for careful consideration in their clinical use.

Alpha-blocker therapy may not be needed long-term when combined with finasteride for BPH.

This review discusses the impact of COVID-19 on lower urinary tract symptoms and benign prostatic enlargement, noting altered patient care and management, but provides no new clinical results.

In this study, Leonuri Herba alkaloids significantly reduced prostate hyperplasia indicators and improved urinary parameters in hormone-induced model rats.

This study found that a novel thiohydantoin derivative, 3a, effectively inhibited androgen receptor activity in LNCaP cells and showed promising in vivo results by reducing testosterone-induced prostate changes, outperforming finasteride in mitigating prostate index and histopathological alterations.

This study found that SDG did not significantly affect prostate weight in rats with BPH, but it may reduce serum PAP activity and alter prostate tissue changes induced by Testosterone Propionate.

This study found that finasteride significantly reduced dihydrotestosterone levels but did not provide clear evidence of impaired libido or erectile function compared to placebo in men.